3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER_GOV
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Ovarian Neoplasms
3
Neoplasm Metastasis
3
Fallopian Tube Neoplasms
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Peritoneal Neoplasms
1
Neoplasms
1
Melanoma
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Limited Stage Small Cell Lung Cancer
1
Hepatic Encephalopathy
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Carboplatin
369
Pemetrexed
310
pembrolizumab
303
Cisplatin
244
Paclitaxel
230
Docetaxel
199
Gemcitabine
130
Nivolumab
121
Erlotinib Hydrochloride
114
Bevacizumab
85
osimertinib
78
atezolizumab
65
durvalumab
58
Cetuximab
57
130-nm albumin-bound paclitaxel
56
Gefitinib
52
Ipilimumab
46
Afatinib
38
Drug Therapy
33
Cyclophosphamide
30
Crizotinib
30
Albumin-Bound Paclitaxel
30
Vinorelbine
28
tislelizumab
26
cemiplimab
26
avelumab
23
icotinib
22
Radiotherapy
22
capmatinib
21
Oxaliplatin
21
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Carcinoma, Non-Small-Cell Lung
×
Glucose
×
Clear all
NCT04863248
2023-04-14
PRESERVE 4
G1 Therapeutics, Inc.
Phase 2
Terminated
10 enrolled
14 charts